What’s Next? Five Things To Look Out For In June

Generics Bulletin previews the most noteworthy and anticipated events for June 2025.

What's Next Image
Source: Norstella/Citeline

Today, 1 June, Celltrion’s Stoboclo and Osenvelt (denosumab-bmwo) biosimilars – approved by the FDA in February – are set to follow Sandoz’s late May entry into the US denosumab market.

Under the terms of a settlement reached with Amgen earlier this year that paved the way...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Content

What’s Next? Five Things To Look Out For In July

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for July 2025.

What’s Next? Five Things To Look Out For In June

 
• By 

Generics Bulletin previews the most noteworthy and anticipated events for June 2025.

More from Generics Bulletin

‘Europe Has To Make Up Its Mind’ – Medicines For Europe’s Sieger On The Path Ahead

 
• By 

At an eventful time for the European generics and biosimilars industry, Medicines for Europe interim president and Polpharma CEO Markus Sieger talks about what the European healthcare sector needs and what the off-patent sector can deliver.

FDA Inspection Finds Leaks and Mold at Sun Pharma Halol Facility

 
• By 

Sun Pharma is facing renewed scrutiny after a scathing US Food and Drug Administration inspection at its Halol facility in Gujarat painted a grim picture of a facility operating in disregard of basic pharmaceutical safety standards.

US Federal Circuit Clears Path for MSN to Market Entresto Generic

 
• By 

Novartis has failed to secure a court order to stop MSN from launching a generic Entresto, and has also seen an earlier temporary ban lifted, potentially opening the market to competition before a final decision on a US patent dispute.